Oral Solid Dosage Contract Manufacturing Market to Grow

Oral Solid Dosage Contract Manufacturing Market 2022

The oral solid dosage contract manufacturing market reached a value of US$23.4 billion in 2021 and is expected to expand at a CAGR of 5.9% to reach a valuation of US$43.6 billion Americans by the end of 2032.

Contract research organizations are outsourced companies that contractually support pharmaceutical and biotechnology companies in their clinical and preclinical studies. Manufacturing costs are increasing day by day. As a result, large and small pharmaceutical and biotech companies are focusing their efforts on CDMOs to secure long-term contract manufacturing agreements. This will help companies to stick to fixed manufacturing rates and CDMOs to improve the quality of manufacturing.

Tablets and capsules are the basic types of solid dosage forms. Nowadays, companies are using new technologies to increase the bioavailability of dosage forms to increase patient compliance. Oral solid dosage form contractors introduce new products or upgrade older products. For example, many patients, especially pediatric patients, have difficulty swallowing tablets. Therefore, time-release beads can help optimize the release rate. Companies also make sublingual tablets for quick medication.

Get a free sample of this report @ https://www.persistencemarketresearch.com/samples/25768

The increasing complexity of new drug molecules will drive the growth of the market as CROs and CDMOs provide manufacturing with expertise to help manage the complexity of new molecules. Over the next few years, the development and contract manufacturing industry will be boosted by increased investment in infrastructure development and plant expansion, as well as CDMO’s capabilities to provide fully integrated services.

Since the oral solid dosage contract manufacturing market is consolidated with few key players, it presents many lucrative opportunities for new entrants to gain a foothold in this industry. The increase in strategic collaborations can also prove to be a beneficial factor for market players to expand their footprint.

Company Profiles:

Recipharm AB
AbbVie
Patheon NV (ThermoFisher Scientific)
Catalent Inc.
NextPharma
Capsugel (Lonza Group SA)
Aurobindo Pharma Limited
Siegfried SA
Piramal pharmaceutical solutions
Corden Pharma
Kremoint Pharma Pvt Ltd.
HERMES PHARMA Ltd
Medipaams India Private Limited
Alpex Pharma
Abaris Healthcare Pvt Ltd
Ardena Holdings S.A.
Aphena Pharma Solutions
Actiza Pharmaceutical Private Limited
Sunwin Healthcare PVT. LTD
Saffron Medicare PVT. LTD
Kosher Pharmaceuticals
Dr. Reddy’s Laboratory
GlaxoSmithKline Plc
Boehringer Ingelheim BioXcellence
Aenova Holding

Methodology request @ https://www.persistencemarketresearch.com/methodology/25768

Key insights from market research

The galenic form of tablets accounted for 34% market share in 2021.

Pharmaceutical product development held around half of the overall market share, by value, in 2021.
The immediate release mechanism has a market share of 53.7%.

The limited availability of resources and the increased focus on reducing R&D and operational costs are the main reasons why small and medium-sized pharmaceutical or biotechnology companies are opting for outsourcing. As such, these companies dominate the end-user segment and captured around 32% market share in 2021.

The North American contract manufacturing market for solid oral doses accounted for 25.2% of the global market share.

“Rising strategic collaborations between pharma giants and emerging players will drive the demand for contract manufacturing of oral solid doses over the coming years,” says an analyst at Persistence Market Research.

Market competition:

Leading oral solid dosage contract manufacturing vendors are investing in R&D activities to develop new technologies for the development of solid dosage formulations. Along with R&D investments, major players are also aiming for various expansions to create goodwill and successfully establish their presence in the global market.

In January 2022, Lonza, Forbion and BioGeneration Ventures extended their collaboration to include small molecule development and manufacturing services.

What does the report cover?

Persistence Market Research offers a unique perspective and actionable insights into the Oral Solid Dosage Contract Manufacturing Market in its latest study, presenting a historical demand assessment from 2017 to 2021 and projections for 2022 to 2032.

Access the full report @ https://www.persistencemarketresearch.com/checkout/25768

The research study is based on the dosage form (tablets {conventional release, modified release, chewable tablets, effervescent tablets}, capsules {hard gelatin capsules, soft gelatin} capsules/softgels; powders and granules; lozenges and lozenges) , mechanism (immediate release; delayed release; controlled release), application (pharmaceutical product development; manufacturing of fillers and finishes; packaging/labelling; others) and end user (large pharma/biotech companies; small and medium pharma /biotech; emerging/virtual pharmaceutical companies; nutraceutical companies), in seven key regions of the world.

Access exclusive PMR reports-

CCTV Camera Market- https://www.persistencemarketresearch.com/market-research/cctv-cameras-market.asp

Computer Accessories Market- https://www.persistencemarketresearch.com/market-research/computer-accessories-market.asp

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York, NY 10007 USA
Telephone in the United States – +1-646-568-7751
USA-Canada Toll Free – +1 800-961-0353
Sales – [email protected]

About Us:

Persistence Market Research (PMR), as a third-party research organization, operates through a proprietary fusion of market research and data analytics to help businesses soar high, regardless of the turbulence encountered due to the financial/natural crises.

This press release was published on openPR.

Comments are closed.